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Abstract: Emphysema is largely an under-diagnosed medical condition that can exist in 
smokers in the absence of airway obstruction. We aimed to determine the sensitivity and 
specificity of pulmonary function tests (PFTs) in assessing emphysema using quantitative 
CT scans as the reference standard. We enrolled 224 ever-smokers (current or former) over 
the age of 40. CT of thorax was used to quantify the low attenuation area (% emphysema), 
and to measure the standardized airway wall thickness. PFTs were used individually and in 
combination to predict their ability to discriminate radiographic emphysema. Significant 
emphysema (>7%) was detected in 122 (54%) subjects. Twenty six (21%) emphysema 
subjects had no evidence of airflow obstruction (FEV1/FVC ratio <70%), while all subjects 
OPEN ACCESS Int. J. Environ. Res. Public Health 2011, 8                 
 
 
1325 
with  >23%  emphysema  showed  airflow  obstruction.  The  sensitivity  and  specificity  of 
spirometry  for  detecting  radiographic  emphysema  were  79%  and  75%,  respectively. 
Standardized airway wall thickness was increased in subjects with airflow obstruction, but 
did not correlate with emphysema severity. In this cohort of lifetime ever-smokers, PFTs 
alone were inadequate for diagnosing emphysema. Airway wall thickness quantified by CT 
morphometry was associated with airflow limitation, but not with emphysema indicating 
that the heterogeneous nature of lung disease in smokers may represent distinct phenotypes.  
Keywords: airflow limitation; chronic obstructive pulmonary disease; CT morphometry; 
emphysema; airway wall thickness; pulmonary function test 
 
1. Introduction 
The prevalence of cigarette smoking continues to rise in most developing countries around the world, 
but in the United States, former smokers now outnumber current smokers [1-3]. Despite smoking cessation, 
recent demographic data suggest that many ever-smokers (herein defined as former or current smokers) 
develop chronic obstructive pulmonary disease (COPD) [4,5]. A complete phenotypic characterization of 
lung disease in smokers is often delayed until the onset of self-reported clinical symptoms and findings of 
airflow obstruction on pulmonary function tests (PFTs), which further obscures the true prevalence and 
extent of tissue  damage  in the smoking population. While newer studies increasingly document the 
genetic  and  immune  factors  critical  to  the  underlying  pathogenesis  of  COPD,  a  comprehensive 
understanding of lung parenchymal destruction in ever-smokers remains elusive [6-8]. 
An exaggerated reduction in Forced Expiratory Volume in 1 second (FEV1), either absolute or 
expressed as a trend over time, has been shown to have an inverse association with life expectancy [9] 
and  previous  studies  have  indicated  that  airflow  limitation  correlated  directly  with  qualitative 
measurements of emphysema in ever-smokers [10-12]. However the degree of airflow obstruction, if 
any, is highly variable even among ever-smokers with equal pack year histories [13].  
The American Thoracic Society (ATS) and European Respiratory Society (ERS) have advocated 
the use of the lower limit of normal (LLN) based on the National Health and Nutrition Examination 
Survey  (NHANES)  data  on  lung  function  in  a  healthy  population  [14,15]  to  diagnose  COPD. 
Alternatively, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has in the last 
decade promoted the use of a fixed FEV1/FVC ratio of less than 70% to diagnose COPD [16]. This 
latter  guideline  is  now  widely  used  to  classify  smokers  with  and  without  COPD.  Based  on  lung 
function  and  symptoms,  smokers  are  categorized  into  one  of  four  GOLD  stages:  mild,  moderate, 
severe  and  very  severe  [16].  There  is  a  lack  of  knowledge  of  the  prevalence  and  natural  history  
of lung parenchymal destruction as seen in emphysema. The importance of determining the presence 
of  emphysema  in  ever  smokers,  independent  of  airway  obstruction,  has  recently  become  more 
recognized  [17].  In  particular,  emphysema  has  been  found  to  be  an  independent  risk  factor  for 
cardiovascular  diseases  [18]  and  is  an  under-detected  clinical  condition  in  ever-smokers. 
Epidemiological  studies  have  shown  that  lung  cancer  risk  is  strongly  related  to  radiographic 
emphysema, independent of airflow obstruction [19-22]. Recently released data from the National Int. J. Environ. Res. Public Health 2011, 8                 
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Lung Screening Trial show that CT scan-based screening of over 53,000 smokers reduced lung cancer 
deaths by 20%; however obtaining CT scans may not be a feasible option for all smokers given the risk 
of  radiation  exposure  and cost concerns [23,24]. Therefore, evaluation of currently available tests 
(such as PFT and spirometry) that may discriminate smokers with emphysema are much needed to 
better identify those who are at a higher risk for lung cancer, and who would benefit most from CT 
scan-based cancer surveillance.  
Past studies have demonstrated that CT diagnosis by visual assessment is closely correlated with 
pathologic  emphysema  grade  [25,26]  and  allows  for  accurate  diagnosis  of  emphysema.  Further, 
qualitative  assessment  of  emphysema  severity  has  been  shown  to  relate  to  FEV1  impairment  and 
airway wall thickness (AWT) [27]. AWT can also be quantified by CT imaging, and has recently been 
shown  to  correlate  with  symptoms  in  COPD  patients  [28,29].  To  gain  further  insight  into  the 
relationships between airflow obstruction and emphysema, we designed a study to determine accuracy 
of pulmonary function testing in the diagnosis of emphysema, as measured by CT morphometry, in a 
cohort of ever-smokers [30,31]. A second aim of the study was designed to evaluate the relationship of 
airway wall thickness (AWT), with airflow obstruction and with the degree of (%) emphysema. A 
portion of this work was recently reported as an abstract [32].  
2. Materials and Methods 
2.1. Clinical and Demographic Characteristic of the Study Participants  
We prospectively recruited 224 ever-smokers as part of the Longitudinal Exacerbation Study of 
COPD (LES-COPD). Enrollment criteria included age over 40, no history of concurrent lung cancer, 
chest surgery, or chronic lung diseases other than COPD (e.g., sarcoidosis, fibrosis, etc.). Random 
participants  that  met  our  inclusion/exclusion  criteria  were  enrolled  from  local  newspaper 
advertisements and at three clinics within the Texas Medical Center, in Houston, Texas: the Ben Taub 
General Hospital, Baylor Clinic, and Michael E. DeBakey Veterans Administration (VA) hospital. All 
studies were approved by the Institutional Review Board at Baylor College of Medicine (H-18029; 
Longitudinal  Exacerbation  Study  of  COPD)  and  written  informed  consent  was  obtained  from  all  
study participants. 
2.2. Phenotypic Characterization of Former and Current Smokers 
All pulmonary function tests were performed in diagnostic laboratories (Michael E. DeBakey VA 
and BCM clinics) that use standardized equipments and follow ATS/ERS guidelines; if the FEV1 was 
reduced below 80% of predicted or FEV1/FVC was below 70%, the participants received two doses of 
bronchodilator (albuterol 180 microgram) and a repeat measurement of spirometry was performed 
according to the ATS/ERS guidelines [14]. Calculation of all pulmonary function tests, in relation to 
reference  values,  were  performed  using  computer  programs  and  reviewed  by  trained  physicians, 
without knowledge of the CT morphometry results. Normative values for spirometry were based on 
NHANES III data and absolute lung volumes were measured using plethysmograph [33]. Lung volume 
normative values were based on the equations endorsed by the ERS [15], with the upper limits of 
normal (ULN) calculated based on the 95% confidence interval. The current ATS/ERS guidelines [14], Int. J. Environ. Res. Public Health 2011, 8                 
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do not recommend a single reference equation for the DLCO, due to measurement variability among 
laboratories; we calculated our normal values based on three representative equations: Crapo [34], 
Cotes [35], and Miller [36], and used the latter equation as the most optimal predictive values with the 
lower limit of normal (LLN) calculated based on the 95% confidence interval. 
2.3. Quantitative CT Morphometry Assessment of Emphysema 
CT scans of the lung were acquired with the subject in supine position during end-inspiratory breath 
holding  using  a  Siemens  Cardiac  Sensation  Cardiac  scanner  (Siemens  Medical  Solutions).  The 
subjects were coached to take a full breath, with imaging parameters of 120 kVp, 130 100 mAs and a 
pitch of 1.75. The images were reconstructed at 1 and 5 mm thickness using both an intermediate (b35f) 
and  a  high  (b65f)  spatial  frequency  reconstruction  algorithm.  The  de-identified  CT  images  were 
archived on to CDs, sent to the University of British Columbia (UBC), and were analyzed using the 
previously  validated  EmphylxJ  custom  software  [30,37].  Briefly,  emphysema  was  assessed  by 
segmenting the lung parenchyma from the chest wall and large central blood vessels using a modified 
border tracing with a prior position-knowledge algorithm. A value of greater than 7% Low Attenuation 
Area (%LAA) below −950 HU was used as the upper limit of non-emphysematous lung; this value has 
been carefully validated with macroscopic and microscopic evaluation of lung tissue, which found that 
6.8% LAA represents the upper limit of non-emphysematous lung [25,26,37,38].  
2.4. Measurement of Airway Wall Thickness 
The airway wall thickness (AWT) was determined using the algorithm as previously devised at 
iCAPTURE  center  at  UBC  [39].  Briefly,  airways  that  were  cut  in  an  acceptable  cross  section 
(long/short internal diameter 2.2 or less) were identified and AWT analysis was performed using the  
1  mm  thick  CT  images.  Every  10
th  image  was  chosen  using  the  spatial  frequency  reconstruction 
algorithm CT (b65f), to sample unique airways; on average 39 ±  23 airways per subject were measured 
(minimum = 5, maximum = 118). Briefly, a seed point was placed in the lumen of the airway, and 
radial lines were drawn to find the internal and external points at which the X-ray attenuation value 
was  half  the  maximum  value  within  the  wall  as  we  have  described  [40,41].  A  standardized 
measurement  of  AWT  was  obtained  to  minimize  sampling  bias;  the  measurements  of  internal 
perimeter  (Pi)  was  correlated  with  the  square  root  of  airway  wall  area  for  each  subject  as  
described [40,41]. 
2.5. Statistical Analysis 
Since  the  data  were  not  normally  distributed,  the  degree  of  linear  association  between  two 
continuous  measures  was  assessed  using  Pearson’s  correlation  coefficient.  Comparisons  between 
unmatched pairs were performed using the Mann-Whitney U non-parametric test. Test characteristics 
for  PFT  (sensitivity,  specificity,  likelihood  ratios,  and  predictive  values)  were  calculated  using 
previously described formulas [15,42] and using CT quantified emphysema (%LAA) with ≥7% as the 
reference standard [25,26,37,38]. Test characteristics were also calculated for combinations of PFTs, 
whereas if any component of the combination is positive, the combination is considered positive. Each Int. J. Environ. Res. Public Health 2011, 8                 
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combination  includes  FEV1/FVC  <  70%,  as  this  is  the  current  standard  for  diagnosis  of  COPD. 
Positive  (PPV)  and  negative  (NPV)  predictive  values  were  also  calculated  based  on  this  study 
population, as the exact prevalence of anatomic emphysema in ever-smokers has not yet been defined 
in the U.S. or worldwide populations. Statistical significance was defined as a p value less than 0.05. 
3. Results  
3.1. Demographics Distributed by GOLD Classification and CT Evidence of Emphysema 
In all, 235 ever smokers were enrolled, of which five were excluded or withdrew consent. Six 
subjects performed PFT, but failed to obtain CT scan, therefore the analyses included data collected 
from  224  subjects  that  completed  both  PFT  and  CT  (Figure  1A).  The  clinical  and  demographic 
characteristics of study subjects, categorized by GOLD criteria, are shown in Table 1. 
Figure 1. Schematic overview of the study design and FEV1% predicted and FEV1/FVC ratio 
among ever-smokers. (A) Flowchart of the recruitment, exclusions, dropouts, measurements, 
and  results  in  evaluating  the  diagnostic  accuracy  of  spirometry  (FEV1/FVC  <  70%)  in  
the  detection  of  emphysema,  as  defined  by  CT  quantification  (Low  Attenuation  Area;  
LAA ≥ 7%) is shown. The number of participants recruited, excluded, and measured is 
shown within the respective boxes. 
# Four subjects were excluded (three for concomitant 
lung  disease;  one  for  α-1-antitrypsin  deficiency). 
¶   Six  total  subjects  did  not  have  CT 
performed  (two  expired;  three  lost  to  follow-up;  one  withdrew  consent).  (B)  FEV1% 
predicted was plotted by age group among current (N = 133, solid circles) and former  
(N = 91, open circles) smokers. (C) FEV1/FVC ratio was plotted by age group among 
current (N = 133, solid circles) and former (N = 91, closed circles) smokers. The group 
means  are  depicted  by  solid  (current  smokers)  and  dashed  (former  smokers)  lines.  
* P < 0.05 current smokers versus former smokers. 
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Table 1. The clinical and demographic characteristics of study subjects, categorized by GOLD criteria. 
Stage 
NGC 
(previously 
Stage 0) 
COPD (GOLD) 
(I)  (II)  (III)  (IV) 
Number  102  18  55  39  10 
Age, mean (± s.d.)  53 ±  8  55 ±  9  64 ±  9  64 ±  9  59 ±  7 
Height, cm (± s.d.)  170 ±  9  174 ±  11  174 ±  9  175 ±  8  173 ±  8 
Weight, kg (± s.d.)  88 ±  21  79 ±  12  88 ±  18  80 ±  19  74 ±  16 
Male, no. (%)  42 (41%)  14 (78%)  46 (84%)  35 (90%)  8 (80%) 
Ethnicity, no. (%)           
Black  60 (59%)  7 (39%)  12 (22%)  13 (33%)  2 (20%) 
Hispanic  4 (4%)  1 (6%)  1 (2%)  1 (3%)  1 (10%) 
White  35 (34%)  13 (56%)  42 (76%)  25 (64%)  7 (70%) 
Other  3 (3%)  0 (0%)  0 (0%)  0 (0%)  0 (0%) 
Smoking status, no. (%)           
Current   72 (71%)  14 (78%)  29 (53%)  14 (36%)  4 (40%) 
Former  30 (29%)  4 (22%)  26 (47%)  25 (64%)  6 (60%) 
Pack-years, mean (± s.d.)  33 ±  30  40 ±  18  69 ±  41  66 ±  35  62 ±  24 
Quitting years, mean (± s.d.)  14 ±  11  21 ±  11  12 ±  11  9 ±  10  9 ±  6 
Lung Function           
%FEV1 (± s.d.)  92 ±  15  90 ±  7  64 ±  8  39 ±  5  25 ±  3 
FEV1/FVC ratio (± s.d.)  78 ±  5  66 ±  4  56 ±  8  42 ±  8  34 ±  5 
%DLCO (± s.d.)  78 ±  16  63 ±  20  59 ±  14  42 ±  15  35 ±  13 
NGC: ―Not GOLD Classified,‖ current and former smokers without airflow obstruction; s.d.: standard 
deviation; cm: centimeters; kg: kilograms; no.: number; %FEV1: forced expiratory volume in 1 second, 
percent of predicted (post-bronchodilator); FVC: forced vital capacity; %DLCO: diffusing capacity for 
carbon monoxide, percent of predicted; pack-years: number of years smoked multiplied by packs per 
day; quitting years: number of years since last reported smoking activity. 
A total of 102 participants did not meet GOLD criteria for COPD (i.e., FEV1/FVC < 70%) and were 
thus labeled as not GOLD classified (NGC). When FEV1% predicted and FEV1/FVC ratio (%) were 
plotted by age group [Figures 1(B,C)], we found that individuals >60 years of age had more severe 
disease than the younger individuals, though each group is well represented in our study population. 
The  demographic  and  clinical  characteristics  of  the  study  subjects,  categorized  by  presence  or 
absence  of  CT-based  emphysema  using  low  attenuation  area  (LAA)  are  shown  in  Table  2.  The 
stratification that distinguishes patients with significant emphysema defined as ≥7% in ever-smokers is 
based on published studies using a healthy cohort as control subjects where CT images were analyzed 
using  custom  software  (EmphylxJ)  as  previously  described  [43,44].  Slightly  older  subjects  and 
predominantly former smokers were over-represented in the emphysema group, compared with the 
group without emphysema. Those with emphysema ≥7% had significantly lower FEV1% of predicted, 
FEV1/FVC ratios and DLCO% of predicted than those without significant emphysema.  
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Table 2. Clinical and demographic information of the study participants when separated by 
CT quantification. 
CT Quantification 
LAA < 7% 
No emphysema 
LAA ≥ 7% 
Emphysema 
Number  102  122 
Age, mean (± s.d.)  53 ±  8  62 ±  10 
Height, cm (± s.d.)  170 ±  10  174 ±  9 
Weight, kg (± s.d.)  85 ±  20  86 ±  19 
Male, no. (%)  45 (44%)  100 (82%) 
Ethnicity, no. (%)     
Black  59 (58%)  35 (29%) 
Hispanic  4 (4%)  4 (3%) 
White  37 (36%)  82 (67%) 
Other  2 (2%)  1 (1%) 
Smoking status, no. (%)     
Current  84 (82%)  49 (40%) 
Former  18 (18%)  73 (60%) 
Pack-years, mean (± s.d.)  41 ±  36  56 ±  36 
Quitting years, mean (± s.d.)  13 ±  13  12 ±  10 
Lung function     
%FEV1 (± s.d.)  87 ±  18  62 ±  26 
FEV1/FVC (± s.d.)  74 ±  10  55 ±  16 
%DLCO (± s.d.)  74 ±  16  57 ±  22 
CT:  computerized  tomography;  LAA:  low  attenuation  area  (%  emphysema)  by  CT  quantification;  
s.d.:  standard  deviation;  cm:  centimeters;  kg:  kilograms;  no.:  number;  %FEV1:  forced  expiratory 
volume in 1 second, percent of predicted (post-bronchodilator); %DLCO: diffusing capacity for carbon 
monoxide, percent of predicted; pack-years: years smoked x packs per day; quitting years: number of 
years since last reported smoking activity. 
3.2. Diagnostic Value of Pulmonary Function Tests in Emphysema  
We  next  measured  the  sensitivity  and  specificity  of  individual  pulmonary  function  tests  for 
predicting emphysema (LAA ≥ 7%) (Table 3). Positive and negative likelihood ratios (LR+, LR− 
respectively),  and  positive  and  negative  predictive  values  (PPV  and  NPV  respectively)  for  each 
pulmonary function test were also determined (Figure 2). 
The sensitivity and specificity of FEV1/FVC < 70% were 79% and 75%, respectively for detecting 
emphysema. Similar sensitivity and specificity were found when using NHANES reference values 
(73%  and  74%  respectively),  indicating  that  both  cutoff  values  are  similar  for  the  detection  of 
significant emphysema in our cohort. The PPV and NPV for FEV1/FVC < 70% were 79% and 75%, 
respectively. The only pulmonary function test that met the threshold (LR+ > 10; LR− < 0.1) for a 
conclusive test in identifying emphysema was, TLC > upper limit of normal (ULN) (Figure 2). 
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Table 3. Individual pulmonary function tests as predictors of radiographic emphysema. 
Criteria 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
LR+  LR−  PPV %  NPV % 
FEV1/FVC < 70%  79 (71–85)  75 (65–82)  3.09  0.29  79  75 
FEV1/FVC < LLN (NHANES)  73 (65–80)  74 (64–81)  2.76  0.37  77  68 
FEV1 < LLN  67 (59–75)  74 (64–81)  2.54  0.45  75  65 
FEV3/FVC < LLN  62 (53–70)  71 (62–79)  2.11  0.54  71  61 
FEF25–75 < LLN  68 (59–76)  43 (34–53)  0.68  2.32  59  54 
RV > ULN  52 (43–61)  92 (86–96)  6.64  0.52  89  62 
TLC > ULN  22 (16–30)  98 (94–100)  11.38  0.79  93  52 
RV/TLC > ULN  46 (38–55)  94 (88–98)  7.87  0.57  90  60 
DLCO < LLN  91 (84–95)  23 (16–33)  0.91  4.26  59  68 
LLN:  lower  limit  of  normal;  ULN:  upper  limit  of  normal;  CI:  confidence  interval;  LR+:  positive 
likelihood  ratio;  LR−:  negative  likelihood  ratio;  PPV:  positive  predictive  value;  NPV:  negative 
predictive value; %FEV1: forced expiratory volume in 1 second, % of predicted (post-bronchodilator); 
FVC: forced vital capacity; FEV3: forced expiratory volume in 3 seconds; FEF25−75: forced expiratory 
flow between 25% and 75% of expired FVC; RV: residual volume; TLC: total lung capacity, % of 
predicted; %DLCO: diffusing capacity for carbon monoxide, % of predicted. 
Figure  2.  Likelihood  ratios  (LR)  for  detection  of  emphysema  from  pulmonary  
function  tests.  The  positive  (+)  and  negative  (–)  likelihood  ratios  for  detection  of  
emphysema as assessed by individual PFTs are shown where a LR+ of >10, or LR− of 
<0.1  represent  conclusive  increase  in  the  likelihood  of  the  presence,  or  absence  of  
emphysema respectively.  
 
 
However in the absence of airflow obstruction, the TLC was abnormal only three times, yielding a 
specificity of 99% but a sensitivity of only 8%. Combining pulmonary function tests proved no better 
than individual tests in discriminating emphysema (Table 4). As expected, increasing the number of Int. J. Environ. Res. Public Health 2011, 8                 
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abnormal  tests  increased  the  sensitivity  of  discriminating  emphysema  but  resulted  in  drastically 
reduced specificity. For example, the combination of airflow obstruction (FEV1/FVC < 70%), elevated 
lung volumes (RV > ULN and TLC > ULN), and reduced DLCO (<LLN) resulted in 95% sensitivity. 
However,  the  specificity  for  emphysema  using  this  combination  dropped  to  21%.  None  of  the 
combinations  met  likelihood  ratio  criteria  for  a  definitive  test  and  none  of  the  combinations  
out-performed an FEV1/FVC < 70% with regards to LR+.  
Table 4. Combined pulmonary function tests as predictors of radiographic emphysema. 
Criteria 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
LR+  LR− 
FEV1/FVC < 70% and FEV1/FVC < LLN (NHANES)  79 (71–85)  74 (64–81)  2.97  0.29 
FEV1/FVC < 70% and RV/TLC > ULN  79 (72–87)  72 (62–80)  2.79  0.29 
FEV1/FVC < 70% and FEV1 < LLN  80 (73–87)  63 (53–72)  2.16  0.31 
FEV1/FVC < 70% and FEV3/FVC < LLN  80 (72–87)  65 (54–73)  2.27  0.31 
FEV1/FVC < 70% and TLC > ULN  80 (72–87)  74 (64–81)  3.03  0.27 
FEV1/FVC < 70% and RV > ULN  81 (73–87)  70 (60–78)  2.66  0.27 
FEV1/FVC < 70% and RV > ULN and TLC > ULN  82 (74–88)  70 (60–78)  2.69  0.26 
FEV1/FVC < 70% and FEF25−75 < LLN  84 (77–90)  38 (29–48)  1.36  0.41 
FEV1/FVC < 70% and FEV1 < LLN and FEV3/FVC < LLN  
and FEF25−75 < LLN 
87 (80–92)  27 (19–37)  1.20  0.48 
FEV1/FVC < 70% and FEV3/FVC < LLN and DLCO < LLN  93 (87–97)  16 (10–25)  1.11  0.42 
FEV1/FVC<70% and DLCO<LLN  93 (87–97)  21 (14–30)  1.19  0.32 
FEV1/FVC < 70% and DLCO < LLN and RV/TLC > ULN  93 (87–97)  21 (14–30)  1.19  0.32 
FEV1/FVC < 70% and DLCO < LLN and RV > ULN  94 (89–97)  21 (14–30)  1.20  0.28 
FEV1/FVC < 70% and FEF25−75 < LLN and DLCO < LLN  95 (90–98)  13 (8–21)  1.09  0.39 
FEV1/FVC < 70% and DLCO < LLN and TLC > ULN  95 (90–98)  21 (14–30)  1.21  0.24 
FEV1/FVC < 70% and DLCO < LLN and RV > ULN and  
TLC > ULN 
95 (90–98)  21 (14–30)  1.21  0.24 
FEV1/FVC < 70% and FEF25−75 < LLN and DLCO < LLN and  
RV > ULN and TLC > ULN 
97 (92–99)  13 (8–21)  1.11  0.26 
* LR+ = positive likelihood ratio; LR− = negative likelihood ratio; LLN = lower limit of normal;  
ULN = upper limit of normal; FEV1 = forced expiratory volume in 1 second (post-bronchodilator);  
FVC  =  forced  vital  capacity;  FEV3  =  forced  expiratory  volume  in  3  seconds;  FEF25−75  =  forced 
expiratory flow between 25% and 75% of expired FVC; RV = residual volume; TLC = total lung 
capacity; DLCO = diffusing capacity for carbon monoxide. 
The predictive value of FEV1/FVC < 70% and TLC>ULN were only 21% sensitive, but was 99% 
specific for emphysema with LR+ of 21.07 and PPV of 96%. Combining FEV1/FVC < 70% with other 
lung  volume  measurements,  such  as  RV  >  ULN  (LR+  16.86,  PPV  95%)  or  RV/TLC  >  ULN  
(LR+  15.45,  PPV  95%)  produced  similar  results.  The  combination  of  all  spirometry  measures 
(FEV1/FVC, FEV1, FEV3/FVC, and FEF25−75) produced a sensitivity of 48% and specificity of 88%, 
while combining FEV1/FVC < 70% and DLCO < LLN produced a sensitivity of 74% and specificity 
of 80%.  Int. J. Environ. Res. Public Health 2011, 8                 
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3.3. Correlation between CT Emphysema and Pulmonary Function Tests 
We found a significant negative correlation between the severity of emphysema, as quantified by 
CT  morphometry  (%LAA,  representative  samples  are  shown  in  [Figures  3(A,B)])  with  FEV1/FVC  
(Figure 3C), and DLCO% predicted (Figure 3D). The negative correlation between % emphysema and 
FEV1/FVC was virtually identical in current and former smokers but there was a significant difference 
in the Y intercept of the correlation line in current when compared to former smokers.  
Figure 3. Correlation between PFTs and % emphysema in ever-smokers. Representative 
quantitative CT images of lung (left images) are matched to conventional CT images of the 
same lung (right images) from individuals without (A) and with (B) emphysema. Yellow 
background  within  lung  margins  (left  images)  was  quantified  as  a  percent  of  whole  
lung  to  determine  the  percent  emphysema  (1%  and  40%,  respectively;  see  Methods).  
(C) FEV1/FVC ratio was plotted against % emphysema, with regression lines in current  
(N = 133; solid line) and former (N = 91; dashed line) smokers. P < 0.0001; r = −0.7136 
and r = −0.7574 Goodness of Fit for current and former smokers respectively. The lines are 
similar in slope (P = 0.78) and elevation (P = 0.17). The graph is divided into quadrants 
based on cutoff values for FEV1/FVC (70%) and % emphysema (7%). Additional dashed 
lines identify FEV1/FVC 78% (horizontal) and 23% emphysema (vertical). (D) DLCO% 
predicted plotted against % emphysema with regression lines in current (N =126; solid line) 
and  former  (N  =89;  dotted  line)  smokers.  P  <  0.0001;  r  =  −0.4690  and  r  =  −0.7074 
Goodness of Fit for current and former smokers respectively. The lines are significantly 
different in elevation (p = 0.0003) but not slope (P = 0.79). The graph is separated into 
quadrants based on cutoffs for DLCO% (75%) and % emphysema (7%).  
 
 
The FEV1/FVC ratio demonstrated a stronger correlation with % emphysema in current (r = −0.71, 
P < 0.0001) and former smokers (r = −0.76, P < 0.0001) than either FEV1% or DLCO%. All subjects 
with LAA > 23% (vertical dashed line) also demonstrated FEV1/FVC < 70%, with 26 subjects with 
FEV1/FVC ≥ 70% demonstrating significant radiographic emphysema (LAA range 7–23%). The mean 
age of this group was 52 ±  7 indicating that emphysema in these ever-smokers is not due to lung 
parenchymal senescence reported in the aging population [45]. While no reasonable FEV1/FVC cutoff Int. J. Environ. Res. Public Health 2011, 8                 
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excluded emphysema, a cutoff of 78% excluded 94% of ever smokers with emphysema (horizontal 
dashed line). 
3.4. Airway Wall Thickness Is Associated with Airway Obstruction but Not Emphysema  
In this cohort, we determined that all ever-smokers with >23% emphysema had concurrent airflow 
obstruction. Therefore, we next analyzed the contribution of airway wall thickness (AWT-Pi10) to 
airflow obstruction and emphysema, in a subgroup of ever-smokers with >7% and < or equal to 23% 
emphysema (representative images shown in (Figure 4A).  
Figure 4. Airway wall thickness is increased in ever smokers with emphysema and airway 
obstruction. (A) A representative images of the internal perimeter of CT identified airway 
in subjects with similar degree of CT emphysema (11 and 12%) and with (left panel) or 
without (right panel) airflow obstruction. (B) Linear regression correlation of airway wall 
thickness (AWT-Pi10) was versus FEV1/FVC ratio (solid line; P = 0.0005; r = −0.3981) 
and  FEV1%  predicted  (dashed  line;  P  =  0.003;  r  =  −0.3457)  in  73  subjects  with  
% emphysema between 7–23%. (C) AWT was plotted against % emphysema, with linear 
regression in the same group of 73 subjects. The correlation was not significant (P = 0.81,  
r  =  0.0284).  (D)  Airway  wall  thickness  (AWT-Pi10)  measurements  were  assessed  in  
73  ever  smokers  with  similar  degree  of  emphysema  (range  7  to  23%)  comparing  
those with no airflow limitation (FEV1/FVC ≥ 70; N = 24) and with airflow obstruction 
(FEV1/FVC < 70; N = 49).  
 
This subgroup was similar to the overall study participants in terms of age (60 ±  11), pack-years  
(52  ±   36),  FEV1/FVC  (62  ±   13),  FEV1  %  predicted  (73  ±   25).  Analyses  of  AWT-Pi10  showed 
significant correlation between FEV1 % predicted (r = −0.40, P = 0.0005) and FEV1/FVC (r = −0.35,  
P = 0.0027), shown in Figure 4B, but not with %LAA (r = 0.03, P = 0.81, Figure 4C). When smoking Int. J. Environ. Res. Public Health 2011, 8                 
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status was taken into account, former smokers showed a significant correlation between AWT-Pi10 
and FEV1 % predicted (r = −0.40, P = 0.009) and FEV1/FVC (r = −0.56, P = 0.0001), though these 
findings were not seen in current smokers (data not shown). Further, significantly higher AWT-Pi10 
values were found in smokers with airflow obstruction (2.62 mm ±  0.42) compared to smokers without 
airflow obstruction (2.29 mm ±  0.40; P-value = 0.0001) (Figure 4D). 
4. Discussion and Conclusions  
In this study we determined the performance characteristics of standard PFTs in discriminating 
emphysema  in  a  well-defined  cohort  of  current  and  former  smokers.  We  further  evaluated  the 
correlations  between  airway  wall  thickness,  airflow  obstruction,  and  emphysema  in  the  same 
population. We found that airflow obstruction, as defined by an FEV1/FVC < 70%, was 79% sensitive 
and  75%  specific  in  discriminating  significant  emphysema.  Combining  FEV1/FVC  <  70%  with  
FEV1 < LLN increased the sensitivity of emphysema detection to 80% but reduced specificity to 63%, 
while other combinations of PFTs decreased specificity further, and failed to improve predictive values. 
Measurement of lung volumes, specifically TLC, was the only method found to meet criteria for a 
definitive test, i.e., a test in which a positive result would rule-in the presence of emphysema. However, 
an abnormally high TLC, in the absence of airflow obstruction, occurred rarely in our population, and 
therefore does not appear to have a practical application in clinical setting for detecting emphysema. 
Conversely, a reduced diffusion capacity was found to be quite sensitive for emphysema, however, this 
test is very non-specific as evidenced by a low LR+ < 1. Further current smokers had significantly 
reduced DLCO when compared to former smokers with the same degree of emphysema. This finding 
is  consistent  with  the  previously  tested  hypothesis  that  active  smoking  acutely  reduces  DLCO 
independent of emphysema by decreasing subjects’ lung capillary blood volume [46].  
We show here that measurement of the FEV1/FVC ratio from simple spirometry demonstrated the 
best combination of sensitivity and specificity for discriminating emphysema and spirometry could be 
performed readily in clinics [15]. In a subset of subjects with less severe emphysema (LAA 7–23%), 
increased airway thickness was associated with airflow obstruction, suggesting that an increase in 
airway wall thickness significantly contributed to airflow obstruction. Further, the failure of emphysema 
severity to correlate with airway wall thickness in this subset suggests that airway disease and anatomical  
emphysema from smoking, at least in part, may represent distinct pathophysiological processes. 
Our findings are of clinical importance to the study of COPD for many reasons. Currently, the exact 
prevalence  of  emphysema  in  smokers  is  unknown  and  we  show  here  that,  consistent  with  prior  
studies, emphysema remains an under diagnosed medical condition [47,48]. Further spirometry based 
classification  of  ever-smokers  with  smoking-related  lung  disease  may  fail  to  include  those  with 
emphysema who do not show reduced FEV1. Our findings here, together with those of others [48,49], 
highlight  the  importance  of  additional  diagnostic  tests  that  could  provide  an  accurate  estimate  of 
concurrent emphysema in ever smokers. We show here that while standard pulmonary function tests 
correlate well with airway wall thickening, they fail to identify a substantial number of ever smokers 
with emphysema. These findings have important implications for the design of future clinical studies  
that should consider a better phenotypic classification of ever-smokers with radiographic assessment  
of emphysema.  Int. J. Environ. Res. Public Health 2011, 8                 
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Individuals with distinct patterns of anatomical emphysema may present with different degrees of 
pulmonary function abnormalities [50]. In this study we found no correlation between airway wall 
thickness and severity of emphysema, with the caveat that we did not measure the transpulmonary 
pressure to control for the elastic recoil pressure. Our findings thus represent an in vivo demonstration 
of the dissociation between airflow limitation, airway wall thickness and anatomical emphysema in 
smokers and suggest that the pathological processes underlying airway obstruction and emphysema are 
likely distinct. With a growing number of interventions and treatments targeted to patients specifically 
with emphysema [51,52], and our current findings that more advanced emphysema (LAA > 23%) is 
always associated with airflow obstruction, it is of increasing clinical importance that these patients 
are identified properly at an earlier stage of their disease.  
Our  findings  underscore  the  need  to  develop  improved  diagnostic  and  prognostic  methods  for 
evaluating ever smokers who will eventually develop irreversible lung parenchymal disease. Chest CT 
evaluation is clearly the standard for detecting early emphysema in vivo, but is limited by cost and the 
long-term  consequences  of  exposure  to  ionizing  radiation  [53].  Improved  diagnostic  methods  are 
essential for answering critical questions regarding the natural history of smoking-related lung disease, 
specifically regarding the relationship of obstructive to destructive lung diseases and whether these 
processes  represent  inexorably  progressive  or  self-limited  conditions.  A  proposed  strategy  in  the 
evaluation of ever smokers may be to measure full pulmonary function tests, including spirometry and 
lung  volumes,  and  diffusion  capacity;  if  spirometry  is  normal  but  hyperinflation,  air  trapping,  or 
reduced  gas  exchange are noted,  a CT should be considered to evaluate for isolated emphysema. 
Detection of emphysema without airflow obstruction may also provide an explanation of symptoms 
such as dyspnea or exercise intolerance in ever smokers with normal spirometry, who might otherwise 
be identified as normal. Future studies are necessary to identify emphysema at an early-stage, and 
smokers who are at risk of developing lung disease where intervention may be more efficacious. In 
summary,  our  data  supports  the  notion  that  emphysema  is  a  pathologic  process  that  occurs  in  a 
substantial proportion of smokers independent of airflow obstruction, and thus highlighting the need 
for a modern approach to the evaluation of this large population of patients. 
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